Zhonghui Biotech-B (02627.HK) under its subsidiary Huierkangxin has been selected as the only vaccine on the national medical insurance innovative drug preliminary review list.

Wisdom Finance APP news, Zhonghui Biotechnology-B (02627.HK) announced that, according to the announcement issued by the National Medical Security Administration on August 12, 2025, in the preliminary review of the list of innovative drugs included in this year's national commercial health insurance, there is only one vaccine product a quadrivalent influenza virus subunit vaccine.